Sign Up
Stories
Bristol Myers Strengthens Neuroscience Portfolio
Share
Advancements in Psychiatric Treatments
BMY Engages in Investor Conferences
Bristol Myers Squibb Investor Conference...
Overview
API
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, strengthening its neuroscience portfolio with the acquisition of KarXT for schizophrenia treatment.
Ask a question
How might the acquisition of Karuna Therapeutics impact Bristol Myers Squibb's market position in the neuroscience drugs market?
In what ways could this acquisition reflect broader trends in the pharmaceutical industry's focus on neuroscience treatments?
What are the potential implications of the acquisition for the treatment of schizophrenia and other neurological disorders?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage